Pancreatic Adenocarcinoma Non-resectable
Conditions
Keywords
pancreatic adenocarcinoma, radiofrequency ablation, Endoscopic ultrasound
Brief summary
the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.
Detailed description
The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ablation (RFA) has been developed in our unit and used in patients with unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis .
Interventions
Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
RADIATIONchemoradiotherapy
Receive chemoradiotherapy
Sponsors
First People's Hospital of Hangzhou
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients in the age group 20 to 80 years * A cytological or histological diagnosis of inoperable PDAC based on multidisciplinary review of cross sectional imaging and cytology or histology results. * Patients who have been deemed unfit for surgical resection of the PDAC subjects who are fit for surgical resection but have declined surgery will also be considered for the study * PDAC patients presenting with jaundice to be considered after a successful biliary drainage * Patients ought to be fit enough to be considered for the study (ECOG performance status 0, 1 or 2) * Patients capable of giving informed consent
Exclusion criteria
* Inability to give informed consent * Pregnancy or breast feeding * ECOG performance status 3 or 4 * Life expectancy less than 3 months * Patients with distant metastases or malignant ascites
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in tumour size as measured on EUS and or CT | 60 days | The tumor size was compared before and after 60 days EUS-RFA |
| Change in serum levels of Ca 19-9 | 60 days | Serum levels of Ca 19-9 was compared before and after 60 days EUS-RFA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival at 6 months | 6 months | Survival rate 6 months after EUS-RFA |
| Overall survival at 12 months | 12 months | Survival rate 12 months after EUS-RFA |
Countries
China
Outcome results
None listed